Skip to main content
Erschienen in:

16.10.2020 | Melanoma

Medical Immunosuppression and Outcomes in Cutaneous Melanoma: A Population-Based Cohort Study

verfasst von: Jessica Bogach, MD, MSc, Frances C. Wright, MD, MEd, Janice Austin, MD, Stephanie Y. Cheng, MSc, Christina Diong, MSc, Rinku Sutradhar, PhD, Nancy N. Baxter, MD, PhD, Nicole J. Look Hong, MD, MSc

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Melanoma and the immune system are intimately related. However, the association of immunosuppressive medications (ISMs) with survival in melanoma is not well understood. The study evaluated this at a population level.

Methods

A cohort of patients with a diagnosis of invasive cutaneous melanoma (2007–2015) was identified from the Ontario Cancer Registry and linked to identify demographics, stage at diagnosis, prescription of immunosuppressive medications (both before and after diagnosis), and outcomes. The demographics of patients with and without prescriptions for ISM were compared. Patients eligible for Ontario’s Drug Benefit Plan were included to ensure accurate prescription data. The primary outcome was overall survival. Cox Proportional Hazards Regression models identified factors associated with mortality, including use of ISM as a time-varying covariate.

Results

Of the 4954 patients with a diagnosis of cutaneous melanoma, 1601 had a prescription for ISM. The median age of the patients was 74 years. Overall, 58.4% of the patients were men (60.5% of those without ISM and 54% of those using ISM; p < 0.001). The use of oral immunosuppression was associated with an increased hazard of death (hazard ratio, 5.84; 95% confidence interval, 5.11–6.67; p < 0.0001) when control was used for age, disease stage at diagnosis, anatomic site, comorbidity, and treatment. Other factors associated with death were increasing age, male sex, increased disease stage, truncal location of primary melanoma, and inadequate treatment. In sensitivity analysis with steroid-only ISM use excluded, survival did not differ significantly (p = 0.355).

Conclusions

The use of immunosuppressive steroids for melanoma is associated with worse overall survival. Use of steroids should be limited when possible.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
10.
Zurück zum Zitat Robert C, Schachter J, Long GV, et al. pembrolizumab versus ipilimumab in advanced melanoma. clinical trial, phase III comparative study, multicenter study, randomized controlled trial, research support, non-U.S. gov’t. N Engl J Med. 2015;372:2521–32. http://dx.doi.org/10.1056/NEJMoa1503093. Robert C, Schachter J, Long GV, et al. pembrolizumab versus ipilimumab in advanced melanoma. clinical trial, phase III comparative study, multicenter study, randomized controlled trial, research support, non-U.S. gov’t. N Engl J Med. 2015;372:2521–32. http://​dx.​doi.​org/​10.​1056/​NEJMoa1503093.
11.
Zurück zum Zitat Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. clinical trial, phase III comparative study, randomized controlled trial, research support, non-U.S. gov’t. J Clin Oncol. 2013;31:616–22. http://dx.doi.org/10.1200/JCO.2012.44.6112. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. clinical trial, phase III comparative study, randomized controlled trial, research support, non-U.S. gov’t. J Clin Oncol. 2013;31:616–22. http://​dx.​doi.​org/​10.​1200/​JCO.​2012.​44.​6112.
12.
Zurück zum Zitat Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. clinical trial, phase iii, comparative study, randomized controlled trial, research support, non-U.S. gov’t. N Engl J Med. 2015;373:23–34. http://dx.doi.org/10.1056/NEJMoa1504030. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. clinical trial, phase iii, comparative study, randomized controlled trial, research support, non-U.S. gov’t. N Engl J Med. 2015;373:23–34. http://​dx.​doi.​org/​10.​1056/​NEJMoa1504030.
26.
Zurück zum Zitat Board TPMPR. Use of the World Health Organization defined daily dose in Canadian drug utilization and cost analyses. In: System TNPDUI, editor. Government of Canada Website2010. Board TPMPR. Use of the World Health Organization defined daily dose in Canadian drug utilization and cost analyses. In: System TNPDUI, editor. Government of Canada Website2010.
29.
Zurück zum Zitat Buajatti E, Chiodo S, Watson T, et al. Ontario Atlas of Adult Mortality 1992–2015, Version 2.0: Trends in Public Health Units. Population Health Analytics Lab, Toronto, ON, 2018. Buajatti E, Chiodo S, Watson T, et al. Ontario Atlas of Adult Mortality 19922015, Version 2.0: Trends in Public Health Units. Population Health Analytics Lab, Toronto, ON, 2018.
Metadaten
Titel
Medical Immunosuppression and Outcomes in Cutaneous Melanoma: A Population-Based Cohort Study
verfasst von
Jessica Bogach, MD, MSc
Frances C. Wright, MD, MEd
Janice Austin, MD
Stephanie Y. Cheng, MSc
Christina Diong, MSc
Rinku Sutradhar, PhD
Nancy N. Baxter, MD, PhD
Nicole J. Look Hong, MD, MSc
Publikationsdatum
16.10.2020
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2021
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-09224-9

Neu im Fachgebiet Chirurgie

Ab sofort gelten die neuen Verordnungsausnahmen für Lipidsenker

Freie Fahrt für Lipidsenker? Das nicht, doch mit niedrigerem Schwellenwert fürs Infarktrisiko und neuen Indikationen hat der G-BA die Verordnungs-Handbremse ein gutes Stück weit gelockert.

Appendizitis und Darminfarkt durch Blinddarm-Lipom

Eigentlich sind Lipome recht harmlos. Im Zäkum können sie jedoch erhebliche Komplikationen mit Darminfarkt und Appendizitis verursachen.

Gluteuslappen nach Rektumkarzinom-Op. schützt vor Abszessen

Die Wunddeckung mit einem autologen Rotationslappen nach Entfernung eines Rektumkarzinoms konnte in einer randomisierten Studie gegenüber dem primären Wundverschluss vor allem in einer Hinsicht punkten: Sie führte deutlich seltener zu präsakralen Abszessen.

Webinar

MedTalk Leitlinie KOMPAKT: S3-Leitline zu peripheren Nervenverletzungen

  • Webinar | 10.02.2025 | 13:00

Über den Weg zur finalen Fassung der S3-Leitlinie "Versorgung peripherer Nervenverletzungen" spricht Prof. Dr. Leila Harhaus-Wähner im MedTalk Leitlinie KOMPAKT. In dem kurzen Video geht es darum, was sich im Vergleich zur vorigen Fassung der Leitlinie geändert hat, welche Aspekte für die tägliche Praxis besonders wichtig sind und was jeder gemäß Leitlinie nun anders oder besser machen sollte.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.